Daraxonrasib

REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human clinical trial evaluating RMC-5127, a RAS(ON) G12V-selective inhibitor. The first-in-human trial, RMC-5127-001 [ NCT07349537 ], is an open-label trial evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings. The trial will enroll patients with RAS G12V–mutated solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non–small cell lung cancer (NSCLC), who have progressed on or are intolerant to prior standard therapies, including targeted treatments. “By bringing RMC-5127 to the clinic, we are building on our well-validated RAS(ON) inhibitor approach and extending it to RAS G12V, the second most common RAS mutation driving human cancers, where there are no approved targeted treatment options,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “As our fifth disclosed mutant-selective RAS(ON) inhibitor and fourth clinical-stage program, RMC-5127 broadens the RAS variant coverage of our growing portfolio and opens a suite of development opportunities aimed at improving outcomes for patients with RAS-driven cancers.” RMC-5127 is an innovative inhibitor that binds to cyclophilin A, creating a complex that selectively recognizes and inhibits the oncogenic RAS(ON) form of the RAS G12V variant. RAS G12V is the second most common driver of RAS-addicted human cancers with approximately 48,000 patients diagnosed in the U.S. 1 each year, predominantly among patients with PDAC, CRC, or NSCLC. About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on LinkedIn . Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding progression of clinical studies and findings from these studies, including the safety, tolerability and antitumor activity of the company’s candidates being studied and the durability of these results; dosing and enrollment in the company’s clinical trials; the potential impact of RMC-5127 for patients with KRAS G12V mutations; and the ability of the company to transform outcomes for patients with RAS-driven cancers. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Revolution Medicines Media & Investor Contact: media@revmed.com investors@revmed.com 1 Estimated using tumor mutation frequencies from Foundation Medicine Insights March 2022 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2023

iStock, Afry Harvy Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off. Suddenly, everyone wants in on the revolution—the RAS-addicted cancer biotech, that is. Merck, allegedly AbbVie, and potentially other pharmas have apparently been in talks to acquire Revolution Medicines in recent months, according to multiple outlets. Merck, the company seemingly most likely to make the purchase, dropped out of a possible deal after talks failed to land on a final price , according to reporting from The Wall Street Journal . An earlier report from The Financial Times suggested that Merck had been seeking a price of $28 billion to $32 billion. That Revolution walked away is indicative of management’s confidence in the pipeline, according to Truist Securities. “In our view, given a potential transaction in the $30 billion range was reportedly being discussed is a nice validation of RVMD’s value and could be a good watermark for other potential suitors to consider,” Truist wrote in a note to investors Monday morning. “We continue to believe that RVMD is well funded and doesn’t need to do a deal.” The news that Merck was out sent Revolution’s shares sliding 16% on Monday morning to $97.91. But still, the buyout rumors have continued churning. As William Blair noted last week: “some [investors are] even placing side bets on how many weeks it will be until Revolution Medicines could be acquired.” Revolution CEO Mark Goldsmith declined to discuss the buyout rumors at the J.P. Morgan Healthcare Conference earlier this month. “But with regard to what are we building, it’s not our goal to build something big,” Goldsmith said. “It’s our goal to build something that’s impactful.” Why Merck Wants Revolution Revolution has been around for more than a decade, launching in 2015 with $45 million and a mission to synthesize natural products to find new molecules. From there, the company refined the plan to focus on RAS(ON) inhibitors, with a first wave of products racking up clinical wins in recent years. In September 2025, lead asset daraxonrasib achieved a 29% confirmed objective response rate as a second-line treatment option for patients with pancreatic cancer who have RAS mutations. In the first-line setting, the therapy achieved a 47% ORR. The FDA took notice too, handing out a Commissioner’s National Priority Voucher in October 2025 that could shorten daraxonrasib’s review time to one to two months. But Revolution has more in the hopper. Truist analysts wondered if management balked at Merck’s offer because they had gotten a glimpse of data from an upcoming Phase III trial of daraxonrasib called RASolute-302 in pancreatic ductal adenocarcinoma (PDAC). Topline results from that test are expected in the first half of this year. The therapy is also in some earlier-stage trials for lung cancer. Besides daraxonrasib, Revolution is developing elironrasib, a RAS(ON) G12C-selective inhibitor for solid tumors. Then there’s zoldonrasib, which is in the busy KRAS G12D solid tumor space. Goldsmith said that Revolution has risen to the top because the asset has shown to be “analogous to placebo” on tolerability. The therapy has also been tested in a larger group of patients than the other investigational agents out there, with trials underway in lung cancer. “So we have a much more mature view of how it behaves,” Goldsmith said. But Revolution’s G12C drug elironrasib is where Merck may have run into trouble closing the deal. The pharma is currently testing a KRAS G12C drug called MK-1084 in Phase III studies, which is much more advanced than Revolution’s offering, which is only in a Phase I trial. The overlap means that the Federal Trade Commission could have balked and required Merck to divest MK-1084 or another pipeline asset, according to Truist. “MRK might have had issues paying for an asset that was going to be redundant,” Truist said. But the pharma does not otherwise have a KRAS pipeline and executives are clearly hungry for deals. “We are not limited from a balance sheet,” CEO Rob Davis said at J.P. Morgan . He said the company could spend “multi tens of billions of dollars.” That’s thanks to Merck’s massively successful oncology business, particularly Keytruda, according to a January 8 note from BMO Capital Markets covering the Revolution rumors. “While a deal with MRK appears to be a no-go today, we won’t rule them out from having interest in the future,” Truist said. Who Else Could Want A Revolution? Had Merck managed to seal the deal, BMO said it would have marked a return to high-value M&A in the biopharma sector. Companies have mainly been sticking to smaller transactions in the $5 billion to under $20 billion range. At J.P. Morgan, one CEO after another said that was their target range. But Revolution is still a hot commodity. Truist offered a laundry list of other Big Pharmas that could be interested as Merck backs away. Eli Lilly, Pfizer and Roche are unlikely bets, because all three have similar pan-KRAS inhibitors in their portfolios. To buy Revolution, they would likely have to abandon those assets. That could happen, given that Revolution’s assets could be better than what those companies are holding, Truist believes. Bristol Myers Squibb, manufacturer of the KRAS G12C therapy Krazati, would make sense as a suitor, according to Truist. That drug, which was picked up from Mirati Therapeutics for $4.8 billion in October 2023, has not proven to be a massive revenue generator, and BMS does not have any further KRAS assets in the pipeline. Novartis could also be interested, the firm noted, despite being mostly preoccupied with radiopharmaceuticals at the moment. But the Swiss pharma does have other small molecules in its pipeline that would not overlap with Revolution and could prove complimentary, Truist said. AbbVie was one of the companies rumored to be interested early on. While management has said they are not pursuing such a transaction, Truist has not ruled them out.